Two Sigma Advisers LP Sells 130,900 Shares of Xencor, Inc. (NASDAQ:XNCR)

Two Sigma Advisers LP trimmed its stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) by 22.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 442,000 shares of the biopharmaceutical company's stock after selling 130,900 shares during the period. Two Sigma Advisers LP owned about 0.63% of Xencor worth $10,157,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Sterling Capital Management LLC raised its holdings in Xencor by 732.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 1,040 shares during the period. KBC Group NV lifted its position in shares of Xencor by 26.0% in the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company's stock valued at $90,000 after acquiring an additional 813 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Xencor by 49.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company's stock valued at $93,000 after acquiring an additional 1,337 shares in the last quarter. Summit Investment Advisors Inc. boosted its stake in Xencor by 22.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company's stock worth $162,000 after purchasing an additional 1,282 shares during the period. Finally, Tower Research Capital LLC TRC grew its position in Xencor by 132.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,865 shares of the biopharmaceutical company's stock worth $181,000 after purchasing an additional 4,482 shares in the last quarter.

Wall Street Analyst Weigh In

XNCR has been the subject of several recent analyst reports. William Blair started coverage on Xencor in a research report on Monday, April 21st. They issued an "outperform" rating for the company. Barclays lowered their target price on Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research note on Thursday, May 8th. Wall Street Zen lowered shares of Xencor from a "hold" rating to a "sell" rating in a research report on Friday, March 14th. Wedbush restated an "outperform" rating and set a $31.00 price target on shares of Xencor in a report on Wednesday, April 30th. Finally, Wells Fargo & Company dropped their price objective on shares of Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. Two analysts have rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Xencor presently has an average rating of "Moderate Buy" and a consensus price target of $29.50.

Xencor Stock Up 1.3%

NASDAQ XNCR traded up $0.10 during trading on Tuesday, reaching $7.67. The company's stock had a trading volume of 585,395 shares, compared to its average volume of 771,438. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $545.95 million, a PE ratio of -2.39 and a beta of 0.99. Xencor, Inc. has a 1-year low of $7.16 and a 1-year high of $27.24. The business has a 50-day moving average price of $9.56 and a 200-day moving average price of $16.55.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.06). The business had revenue of $32.73 million during the quarter, compared to analyst estimates of $23.44 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The firm's revenue for the quarter was up 104.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.11) EPS. On average, research analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Insider Transactions at Xencor

In related news, EVP Nancy Valente sold 4,616 shares of the company's stock in a transaction on Friday, May 2nd. The shares were sold at an average price of $11.03, for a total transaction of $50,914.48. Following the completion of the sale, the executive vice president now directly owns 49,169 shares of the company's stock, valued at approximately $542,334.07. This represents a 8.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.76% of the stock is currently owned by corporate insiders.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.